Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 10 | 2023 | 72 | 6.930 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 5 | 2022 | 16 | 3.710 |
Why?
|
| JC Virus | 4 | 2022 | 12 | 3.000 |
Why?
|
| Myelitis, Transverse | 3 | 2021 | 8 | 2.150 |
Why?
|
| Brain Diseases | 3 | 2021 | 77 | 1.890 |
Why?
|
| Neuromyelitis Optica | 3 | 2024 | 8 | 1.870 |
Why?
|
| Central Nervous System Diseases | 2 | 2022 | 27 | 1.460 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 94 | 1.400 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 58 | 1.400 |
Why?
|
| Autoantibodies | 3 | 2023 | 121 | 1.070 |
Why?
|
| Myasthenia Gravis | 3 | 2021 | 19 | 1.000 |
Why?
|
| Receptors, Cholinergic | 2 | 2021 | 14 | 0.900 |
Why?
|
| Humans | 32 | 2024 | 52513 | 0.890 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2024 | 3 | 0.870 |
Why?
|
| Cost of Illness | 1 | 2024 | 120 | 0.870 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2023 | 5 | 0.850 |
Why?
|
| Colitis | 1 | 2023 | 50 | 0.780 |
Why?
|
| Neoplasms | 2 | 2023 | 1301 | 0.780 |
Why?
|
| Optic Neuritis | 1 | 2022 | 22 | 0.770 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 54 | 0.760 |
Why?
|
| Vaccination | 2 | 2021 | 299 | 0.760 |
Why?
|
| Herpes Zoster | 1 | 2022 | 16 | 0.750 |
Why?
|
| Myositis | 1 | 2021 | 20 | 0.740 |
Why?
|
| Immunologic Factors | 1 | 2022 | 117 | 0.730 |
Why?
|
| Cerebrospinal Fluid | 1 | 2021 | 29 | 0.730 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 39 | 0.720 |
Why?
|
| Spinal Cord | 2 | 2022 | 131 | 0.720 |
Why?
|
| Vertigo | 1 | 2021 | 18 | 0.710 |
Why?
|
| Primary Dysautonomias | 1 | 2021 | 3 | 0.710 |
Why?
|
| Diplopia | 1 | 2021 | 20 | 0.700 |
Why?
|
| Leukocytosis | 1 | 2021 | 12 | 0.700 |
Why?
|
| Headache | 1 | 2021 | 76 | 0.690 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2020 | 12 | 0.690 |
Why?
|
| Male | 15 | 2024 | 26816 | 0.640 |
Why?
|
| Lipoid Proteinosis of Urbach and Wiethe | 1 | 2018 | 1 | 0.600 |
Why?
|
| Calcinosis | 1 | 2018 | 52 | 0.570 |
Why?
|
| HIV Infections | 1 | 2022 | 388 | 0.560 |
Why?
|
| Neuroimaging | 3 | 2023 | 94 | 0.550 |
Why?
|
| Seizures | 1 | 2019 | 209 | 0.550 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 189 | 0.530 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1219 | 0.530 |
Why?
|
| Middle Aged | 8 | 2024 | 13081 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 1535 | 0.410 |
Why?
|
| Adult | 8 | 2024 | 14148 | 0.390 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2022 | 10 | 0.380 |
Why?
|
| West Virginia | 2 | 2022 | 4 | 0.370 |
Why?
|
| Female | 9 | 2024 | 28219 | 0.370 |
Why?
|
| Immunotherapy | 2 | 2022 | 244 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 166 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 478 | 0.300 |
Why?
|
| Hospitalization | 2 | 2024 | 749 | 0.290 |
Why?
|
| Cohort Studies | 2 | 2024 | 1551 | 0.280 |
Why?
|
| Aged | 4 | 2021 | 10181 | 0.260 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6661 | 0.260 |
Why?
|
| Aquaporin 4 | 2 | 2022 | 8 | 0.240 |
Why?
|
| Young Adult | 3 | 2024 | 4326 | 0.220 |
Why?
|
| Brain | 2 | 2021 | 1319 | 0.200 |
Why?
|
| Recurrence | 1 | 2024 | 681 | 0.200 |
Why?
|
| Simplexvirus | 1 | 2022 | 15 | 0.190 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 180 | 0.190 |
Why?
|
| Herpesvirus 3, Human | 1 | 2022 | 32 | 0.190 |
Why?
|
| Central Nervous System | 1 | 2022 | 77 | 0.190 |
Why?
|
| Peripheral Nervous System | 1 | 2021 | 16 | 0.190 |
Why?
|
| Endemic Diseases | 1 | 2021 | 25 | 0.180 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 39 | 0.180 |
Why?
|
| Valsalva Maneuver | 1 | 2021 | 10 | 0.180 |
Why?
|
| Viral Load | 1 | 2021 | 80 | 0.180 |
Why?
|
| Meningitis | 1 | 2021 | 25 | 0.180 |
Why?
|
| Bromocriptine | 1 | 2021 | 5 | 0.180 |
Why?
|
| Disability Evaluation | 1 | 2021 | 92 | 0.180 |
Why?
|
| Dopamine Agonists | 1 | 2021 | 10 | 0.180 |
Why?
|
| Universities | 1 | 2022 | 175 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2021 | 41 | 0.180 |
Why?
|
| Neurologic Examination | 1 | 2021 | 73 | 0.170 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2020 | 3 | 0.170 |
Why?
|
| Prednisone | 1 | 2021 | 102 | 0.170 |
Why?
|
| Neural Conduction | 1 | 2020 | 34 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 123 | 0.170 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 172 | 0.170 |
Why?
|
| China | 1 | 2020 | 134 | 0.170 |
Why?
|
| Acute Disease | 1 | 2021 | 387 | 0.170 |
Why?
|
| Lymphoma | 1 | 2020 | 71 | 0.160 |
Why?
|
| Oligoclonal Bands | 1 | 2019 | 1 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 205 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 188 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 250 | 0.150 |
Why?
|
| Comorbidity | 1 | 2021 | 631 | 0.150 |
Why?
|
| Biopsy | 1 | 2021 | 603 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 195 | 0.150 |
Why?
|
| Globus Pallidus | 1 | 2018 | 10 | 0.150 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 15 | 0.150 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 9 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 872 | 0.150 |
Why?
|
| Age Factors | 1 | 2021 | 1132 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1035 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2018 | 95 | 0.140 |
Why?
|
| Fatigue | 1 | 2018 | 129 | 0.140 |
Why?
|
| Glucose | 1 | 2019 | 358 | 0.140 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 193 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1682 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 290 | 0.130 |
Why?
|
| Prognosis | 1 | 2021 | 2115 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 586 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2021 | 5480 | 0.080 |
Why?
|
| Animals | 1 | 2024 | 13464 | 0.070 |
Why?
|
| Child | 1 | 2018 | 7218 | 0.060 |
Why?
|
| Lactams | 1 | 2018 | 24 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2018 | 15 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2018 | 114 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1045 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 169 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 633 | 0.020 |
Why?
|